Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material.

Diepeveen LE, Laarakkers CMM, Martos G, Pawlak ME, Uğuz FF, Verberne KESA, van Swelm RPL, Klaver S, de Haan AFJ, Pitts KR, Bansal SS, Abbas IM, Fillet M, Lefebvre T, Geurts-Moespot AJ, Girelli D, Castagna A, Herkert M, Itkonen O, Olbina G, Tomosugi N, Westerman ME, Delatour V, Weykamp CW, Swinkels DW.

Clin Chem Lab Med. 2019 May 27;57(6):864-872. doi: 10.1515/cclm-2018-0783.

PMID:
30485171
2.

Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency.

Heeney MM, Guo D, De Falco L, Campagna DR, Olbina G, Kao PP, Schmitz-Abe K, Rahimov F, Gutschow P, Westerman K, Ostland V, Jackson T, Klaassen RJ, Markianos K, Finberg KE, Iolascon A, Westerman M, London WB, Fleming MD.

Blood. 2018 Jul 26;132(4):448-452. doi: 10.1182/blood-2017-03-773028. Epub 2018 Jun 12. No abstract available. Erratum in: Blood. 2018 Sep 20;132(12):1355.

3.

Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.

Panwar B, McCann D, Olbina G, Westerman M, Gutiérrez OM.

BMC Nephrol. 2018 Feb 9;19(1):35. doi: 10.1186/s12882-018-0823-7.

4.

Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material.

van der Vorm LN, Hendriks JC, Laarakkers CM, Klaver S, Armitage AE, Bamberg A, Geurts-Moespot AJ, Girelli D, Herkert M, Itkonen O, Konrad RJ, Tomosugi N, Westerman M, Bansal SS, Campostrini N, Drakesmith H, Fillet M, Olbina G, Pasricha SR, Pitts KR, Sloan JH, Tagliaro F, Weykamp CW, Swinkels DW.

Clin Chem. 2016 Jul;62(7):993-1001. doi: 10.1373/clinchem.2016.256768. Epub 2016 May 12.

PMID:
27173010
5.

A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S; PHI112844 Investigators.

Am J Kidney Dis. 2016 Jun;67(6):861-71. doi: 10.1053/j.ajkd.2015.11.021. Epub 2016 Jan 27.

6.

Short-Term Effects of Blood Transfusions on Hepcidin in Preterm Infants.

Lorenz L, Müller KF, Poets CF, Peter A, Olbina G, Westerman M, Franz AR.

Neonatology. 2015;108(3):205-10. doi: 10.1159/000437132. Epub 2015 Aug 19.

PMID:
26304233
7.

Altered erythropoiesis and iron metabolism in carriers of thalassemia.

Guimarães JS, Cominal JG, Silva-Pinto AC, Olbina G, Ginzburg YZ, Nandi V, Westerman M, Rivella S, de Souza AM.

Eur J Haematol. 2015 Jun;94(6):511-8. doi: 10.1111/ejh.12464. Epub 2014 Nov 11.

8.

Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.

Fertrin KY, Lanaro C, Franco-Penteado CF, de Albuquerque DM, de Mello MR, Pallis FR, Bezerra MA, Hatzlhofer BL, Olbina G, Saad ST, da Silva Araújo A, Westerman M, Costa FF.

Am J Hematol. 2014 Apr;89(4):385-90.

9.

Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy.

Mast AE, Schlumpf KS, Wright DJ, Johnson B, Glynn SA, Busch MP, Olbina G, Westerman M, Nemeth E, Ganz T; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II).

Haematologica. 2013 Aug;98(8):1324-30. doi: 10.3324/haematol.2012.070979. Epub 2013 Feb 26.

10.

Iron homeostasis during cystic fibrosis pulmonary exacerbation.

Gifford AH, Moulton LA, Dorman DB, Olbina G, Westerman M, Parker HW, Stanton BA, O'Toole GA.

Clin Transl Sci. 2012 Aug;5(4):368-73. doi: 10.1111/j.1752-8062.2012.00417.x. Epub 2012 Jun 1.

11.

Increased serum hepcidin levels in patients with porphyria cutanea tarda.

Darwich E, To-Figueras J, Molina-López RA, Deulofeu R, Olbina G, Westerman M, Sánchez-Tápias JM, Muñoz-Santos C, Herrero C.

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e68-74. doi: 10.1111/j.1468-3083.2012.04511.x. Epub 2012 Mar 16.

PMID:
22429447
12.

Hepcidin and disordered mineral metabolism in chronic kidney disease.

Carvalho C, Isakova T, Collerone G, Olbina G, Wolf M, Westerman M, Gutiérrez OM.

Clin Nephrol. 2011 Aug;76(2):90-8.

PMID:
21762639
13.

Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis.

Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, Ulloor J, Zhang A, Basaria S, Ganz T, Westerman M, Bhasin S.

J Clin Endocrinol Metab. 2010 Oct;95(10):4743-7. doi: 10.1210/jc.2010-0864. Epub 2010 Jul 21.

14.

Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization.

Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW.

Haematologica. 2009 Dec;94(12):1748-52. doi: 10.3324/haematol.2009.010322.

15.

Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response.

Katodritou E, Ganz T, Terpos E, Verrou E, Olbina G, Gastari V, Hadjiaggelidou C, Varthaliti M, Georgiadou S, Westerman M, Zervas K.

Am J Hematol. 2009 Aug;84(8):524-6. doi: 10.1002/ajh.21448. No abstract available.

16.

Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.

Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB.

Clin J Am Soc Nephrol. 2009 Jun;4(6):1051-6. doi: 10.2215/CJN.05931108. Epub 2009 Apr 30.

17.

Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin.

Ruivard M, Lainé F, Ganz T, Olbina G, Westerman M, Nemeth E, Rambeau M, Mazur A, Gerbaud L, Tournilhac V, Abergel A, Philippe P, Deugnier Y, Coudray C.

J Hepatol. 2009 Jun;50(6):1219-25. doi: 10.1016/j.jhep.2009.01.029. Epub 2009 Apr 5.

PMID:
19398238
18.

Daily regulation of serum and urinary hepcidin is not influenced by submaximal cycling exercise in humans with normal iron metabolism.

Troadec MB, Lainé F, Daniel V, Rochcongar P, Ropert M, Cabillic F, Perrin M, Morcet J, Loréal O, Olbina G, Westerman M, Nemeth E, Ganz T, Brissot P.

Eur J Appl Physiol. 2009 Jun;106(3):435-43. doi: 10.1007/s00421-009-1031-8. Epub 2009 Mar 21.

PMID:
19306018
19.

Serum hepcidin is significantly associated with iron absorption from food and supplemental sources in healthy young women.

Young MF, Glahn RP, Ariza-Nieto M, Inglis J, Olbina G, Westerman M, O'Brien KO.

Am J Clin Nutr. 2009 Feb;89(2):533-8. doi: 10.3945/ajcn.2008.26589. Epub 2008 Dec 10.

PMID:
19073788
20.

Immunoassay for human serum hepcidin.

Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M.

Blood. 2008 Nov 15;112(10):4292-7. doi: 10.1182/blood-2008-02-139915. Epub 2008 Aug 8.

PMID:
18689548
22.

Effect of genistein and genistein analogs on growth of human prostate tissue in vitro.

Geller J, Olbina G, Miljkovic D, Hoffman RM.

J Med Food. 1999;2(3-4):239-41. doi: 10.1089/jmf.1999.2.239. No abstract available.

PMID:
19281390
23.

New sensitive discovery histoculture model for growth-inhibition studies in prostate cancer and BPH.

Olbina G, Miljkovic D, Hoffman RM, Geller J.

Prostate. 1998 Oct 1;37(2):126-9.

PMID:
9759707
24.

Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell lung cancer by antisense oligonucleotides.

Olbina G, Cieslak D, Ruzdijic S, Esler C, An Z, Wang X, Hoffman R, Seifert W, Pietrzkowski Z.

Anticancer Res. 1996 Nov-Dec;16(6B):3525-30.

PMID:
9042216

Supplemental Content

Loading ...
Support Center